TransMedics Group, Inc. $TMDX Shares Sold by Beaconlight Capital LLC

Beaconlight Capital LLC lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 63.7% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 15,406 shares of the company's stock after selling 27,072 shares during the quarter. Beaconlight Capital LLC's holdings in TransMedics Group were worth $1,023,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of TMDX. Silvant Capital Management LLC purchased a new stake in TransMedics Group in the second quarter valued at $26,000. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group during the third quarter worth approximately $29,000. North Star Investment Management Corp. acquired a new stake in TransMedics Group in the 1st quarter valued at $30,000. Ascentis Independent Advisors acquired a new stake in shares of TransMedics Group in the first quarter valued at about $30,000. Finally, Allworth Financial LP raised its holdings in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company's stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMDX has been the subject of a number of recent research reports. Wall Street Zen cut shares of TransMedics Group from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Canaccord Genuity Group restated a "buy" rating and issued a $124.00 target price on shares of TransMedics Group in a research report on Tuesday, June 30th. Needham & Company LLC decreased their price objective on shares of TransMedics Group from $142.00 to $106.00 and set a "buy" rating on the stock in a report on Monday, August 3rd. TD Cowen reissued a "buy" rating and set a $120.00 target price on shares of TransMedics Group in a research note on Wednesday, July 1st. Finally, Stifel Nicolaus raised their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the company a "hold" rating in a research report on Thursday, June 18th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $124.18.

TransMedics Group Price Performance

TMDX stock opened at $88.43 on Monday. The stock has a market cap of $3.06 billion, a P/E ratio of 22.73 and a beta of 1.90. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The company's 50 day moving average is $79.04 and its two-hundred day moving average is $93.59.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company's quarterly revenue was up 20.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.92 EPS. Research analysts expect that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the company's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source